Status:

RECRUITING

Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial

Lead Sponsor:

Seoul National University Bundang Hospital

Collaborating Sponsors:

Ajou University School of Medicine

The Catholic University of Korea

Conditions:

Diabetes Mellitus, Type 2

Bariatric Surgery

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to ...

Detailed Description

Most Asian patients undergoing metabolic surgery for the treatment of T2DM have BMI as low as 30-35 kg/m2. If SG is performed for the treatment of T2DM in these patients, weight may decrease after the...

Eligibility Criteria

Inclusion

  • Age over 18 years
  • BMI equal to or greater than 27.5 kg/m2
  • T2DM duration ≤ 10 years
  • Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication
  • C-peptide level higher than 1.0 ng/mL
  • Presence of type 2 diabetes fulfilling the following criteria
  • Consent to not become pregnant for at least 1 year after surgery
  • Willingness to provide voluntary informed consent

Exclusion

  • Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy)
  • History of previous metabolic surgery for T2DM
  • History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery
  • Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders
  • Suicidal attempts within the last 12 months
  • Treatment for alcohol and drug abuse within the last 12 months
  • Vulnerability factors (lacking mental capacity, pregnancy or planning of pregnancy, lactation)
  • Unsuitability as per the discretion of the researcher

Key Trial Info

Start Date :

January 3 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 3 2036

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT05211375

Start Date

January 3 2022

End Date

January 3 2036

Last Update

January 27 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Seoul National University Bundang Hospital

Seongnam-si, South Korea, 13620